Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

ATLANTA, Nov. 10 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), a biopharmaceutical firm developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2008 financial results and provided an operational update.

Robert McNally, GeoVax's President and CEO, commented, "We are very pleased with the progress we've made during the third quarter of 2008 and for the year so far, as we've taken steps to address both short-term and long-term goals. We made a shipment of the vaccine to the HIV Vaccine Trials Network during October, which is a significant step in preparation for the largest clinical trial yet to be undertaken by GeoVax and we look forward to HVTN's initiation of the Phase 2a trial later this year. We are also nearing completion of a license with Vivalis S.A., a French biopharmaceutical company, for manufacturing platform technology for the MVA portion of our vaccine that we anticipate will significantly improve the long-term production capabilities for the vaccine."

Financial Results for the Three Months and Nine Months Ended September 30, 2008

The Company recorded a net loss of $722,108 for the three months ended September 30, 2008, compared to $1,165,519 for the same period in 2007. For the nine months ended September 30, 2008, the Company's net loss was $2,688,970 as compared to $3,085,926 in 2007. Net losses for 2008 were partially offset by grant revenues of $1,322,502 and $2,298,571 for the three month and nine month periods, respectively, related to the Company's grant from the National Institutes of Health (NIH) in support of its HIV/AIDS vaccine development activities. As of September 30, 2008, the Company reported cash balances totaling $2,784,706.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operation
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Patent and Trademark Office (PTO) has issued a patent ... for weight loss. NB32 is a fixed-dose combination of ... U.S. Patent No. 8,815,889 claims methods for treating insulin ... patent expires in 2024. If NB32 is approved for ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ... , M.D., President and Chief Executive Officer, will present at ... Conference in New York on Tuesday, ... A live and archived webcast of the presentation will be ... the "News & Events" section. About Oncothyreon ...
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... The orders consist of three large odour control systems for ... "These orders are consistent with the market resurgence ... Bruijns , President and CEO. "After a difficult period of ... now beginning to see sales growth. Our lower cost structure, ...
(Date:9/2/2014)... 2, 2014  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the United States Patent & ... in the month of August that are part of ... The issued patents are: , U.S.RE45,065 ... 19, 2014; and , U.S.RE45,095 issued August 26, ...
Breaking Biology Technology:Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... Third Wave Technologies is appointing more new ... to a press release. , ,Maneesh Arora, 37, will become ... has held senior positions in marketing and operations for the ... 35, will be vice president of finance. , ,John Bellano, ...
... investments in 2005 added up to more than $19 million ... report released on Wednesday. , ,The investor tax credits offered ... start to officially track the volume of investments by individuals. ... picture we've had of what's going on in the individual ...
... of financing is vital to a biotech company (it is ... "biotech" in the broadest sense) companies are continually faced with ... development cycle, this week's article will focus on venture capital ... on VC financing results from Burrill and Company's data. Burrill's ...
Cached Biology Technology:State tracks more angel investment, at least $19M last year 2U.S. VC funding flat in 2005 while life science funding grows 2U.S. VC funding flat in 2005 while life science funding grows 3U.S. VC funding flat in 2005 while life science funding grows 4
(Date:9/1/2014)... in the U.S. undergoes a battery of tests designed ... disease. Thousands of children born in the developing world, ... from the disease each year. , A.J. Kumar ... of those deaths. , A Post-Doctoral Fellow in ... George Whitesides, the Woodford L. and Ann A. Flowers ...
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... are labeled a “night owl?report more pathological symptoms related ... for their nocturnal sleeplessness by extending their time in ... time, according to a study published in the April ... (JCSM). , The study, authored by Jason C. Ong, ...
... Southwestern Medical Center have found a new method for ... the most common acute infections in children. , ... by tracking down the virus or bacteria causing it. ... virus may not be present in the blood or ...
... Institutes of Health have discovered how a defect in ... several genes interact to create myelin, a fatty coating ... reliability of their electrical signals. , The discovery ... These disorders can affect the peripheral nervous system—the nerves ...
Cached Biology News:'Night owls' report more insomnia-related symptoms 2Infection detectives use disease 'fingerprints' to track common infections in children 2Infection detectives use disease 'fingerprints' to track common infections in children 3Researchers discover gene crucial for nerve cell insulation 2Researchers discover gene crucial for nerve cell insulation 3
Request Info...
FITC~Bovine Serum Albumin...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Biology Products: